By Digifin Pty Ltd · About this coverage
Key Points
- Multi-year Implicity remote cardiac monitoring contract with NHCS
- Estimated value about A$0.625m over three years, subject to patient volumes
- Annual recurring revenue about A$0.21m over the three-year term
- Covers CIED patients including pacemakers, ICDs and CRT devices
- Implementation expected shortly; pricing and patient numbers confidential
About Hydrix (ASX:HYD)
Hydrix Limited is an ASX-listed technology company headquartered in Melbourne. Through Hydrix Medical it distributes cardiovascular technologies, including remote cardiac monitoring platforms, across Australia and Asia-Pacific.
Hydrix (ASX:HYD) Medical has secured a multi-year contract with National Heart Centre Singapore to deploy the Implicity cloud-based remote cardiac monitoring platform.
Estimated contract value is approximately A$0.625 million over three years, subject to patient volumes monitored under the platform, with annual recurring revenue approximately A$0.21 million over the agreed three-year term. Under the agreement, NHCS will implement the Implicity platform to assist in the remote monitoring of patients with Cardiac Implantable Electronic Devices, including pacemakers, implantable cardioverter defibrillators and cardiac resynchronisation therapy devices. Implementation is expected to commence shortly, with cloud deployment delivered by Implicity and Hydrix Medical, and revenue flowing to Hydrix upon implementation.
Pricing and patient numbers are commercial-in-confidence. The A$0.625 million figure is an estimate subject to patient volumes, not a fixed committed total.
Source: Hydrix Limited (ASX:HYD), 17 September 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.